U.S. markets closed
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • Dow 30

    34,479.60
    +13.36 (+0.04%)
     
  • Nasdaq

    14,069.42
    +49.09 (+0.35%)
     
  • Russell 2000

    2,335.81
    +24.40 (+1.06%)
     
  • Crude Oil

    70.78
    +0.49 (+0.70%)
     
  • Gold

    1,879.50
    -16.90 (-0.89%)
     
  • Silver

    28.05
    +0.02 (+0.07%)
     
  • EUR/USD

    1.2107
    -0.0071 (-0.58%)
     
  • 10-Yr Bond

    1.4620
    +0.0030 (+0.21%)
     
  • GBP/USD

    1.4117
    -0.0060 (-0.42%)
     
  • USD/JPY

    109.6350
    +0.2870 (+0.26%)
     
  • BTC-USD

    35,003.61
    -461.58 (-1.30%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • Nikkei 225

    28,948.73
    -9.83 (-0.03%)
     

Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Inogen INGN reported first-quarter 2020 loss per share of 7 cents, which was narrower than the Zacks Consensus Estimate of a loss of 10 cents. This compares to earnings of 24 cents in the year-ago quarter.

Revenues came in at $88.5 million, which surpassed the Zacks Consensus Estimate by 6.7%. On a year-over-year basis, the top line dropped 1.9%.

Segmental Details

Revenues at the Sales segment amounted to $83.1 million in the quarter under review, down 2% on a year-over-year basis.

Rental revenues grossed $5.34 million, down 0.7% year over year.

Revenues by Region & Category

Business-to-business revenues in the United States amounted to $27.6 million, up 5.7% on a year-over-year basis. Per management, this increase was primarily driven by increased home medical equipment provider demand. 

Internationally, this segment recorded revenues of $20 million, up 1.4% year over year and 3.6% at constant currency. Per management, the increase was primarily led by higher demand in Canada and Australia.

Direct-to-consumer revenues fell 8.9% year over year to $35.5 million in the quarter.This was due to an approximate 15% reduction in average sales representative headcount compared to the year-ago quarter.

Inogen, Inc Price, Consensus and EPS Surprise

 

Inogen, Inc Price, Consensus and EPS Surprise
Inogen, Inc Price, Consensus and EPS Surprise

 

Inogen, Inc price-consensus-eps-surprise-chart | Inogen, Inc Quote

Margins

In the first quarter, gross profit was $38.4 million, down 13.6% year over year. Gross margin came in at 43.4%, down a significant 588 basis points (bps).

Loss from operations in the quarter was $2.2 million against the year-ago quarter’s operating profit of $4.9 million.

Guidance

Due to uncertainty around impact of the COVID-19 on its business, the company has withdrawn its 2020 guidance, issued on Feb 25.

Wrapping Up

Inogen ended the first quarter on a strong note. The company reported growth in business-to-business international and domestic revenues in the quarter.Inogen expects the business-to-business arm to be a strong contributor to revenues in 2020, thanks to the Tidal Assist Ventilator.

On the flip side, significant contraction in gross margin adds to the woes. Also, decline in direct-to-consumer revenues during the quarter is another concern. The company also saw a decline in Sales and Rental segment revenues.

Zacks Rank and Key Picks

Inogen currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Aphria Inc. APHA, Biogen Inc. BIIB and Eli Lilly and Company LLY. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents, comparing favorably with the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million outpaced the consensus estimate by 14.6%. The company carries a Zacks Rank #2 (Buy) at present.

Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.

Eli Lilly delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Biogen Inc. (BIIB) : Free Stock Analysis Report
 
Eli Lilly and Company (LLY) : Free Stock Analysis Report
 
Inogen, Inc (INGN) : Free Stock Analysis Report
 
Aphria Inc. (APHA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.